IDH2 and acute myeloid leukemia: Enasidenib also increased survival rates in IDH2-mutant AML xenografts which supported the initiation of clinical trials of enasidenib in patients with haematologic malignancies with IDH2 mutations (ClinicalTrials.gov Identifier: NCT01915498).